Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVE1642 + fulvestrant
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
AVE1642 + fulvestrant is a combination therapy consisting of **AVE1642**, a humanized monoclonal antibody targeting **insulin-like growth factor 1 receptor (IGF-1R)**, and **fulvestrant**, a selective estrogen receptor degrader (SERD). AVE1642 blocks IGF-1R, a pathway implicated in cancer cell proliferation and resistance to therapy, while fulvestrant degrades estrogen receptors, leading to inhibition of estrogen signaling in hormone-dependent cancers such as breast cancer. The combination was investigated as a treatment for advanced hormone-dependent breast cancer in postmenopausal women. AVE1642 was developed by Sanofi/ImmunoGen and binds IGF-1R with high affinity, down-regulating its downstream signaling pathways. The main modality is monoclonal antibody for AVE1642, and small molecule hormonal therapy for fulvestrant[7][8][4].
- Other names
- anti-IGF-1R monoclonal antibody + fulvestrant
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)ER (Estrogen receptor)
Beyond the preview
Go deeper on AVE1642 + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVE1642 + fulvestrant.